| R. Lewis Dark:
A Common Future for Pathology & Radiology?
DO RADIOLOGISTS AND PATHOLOGISTS have a common future in the age of personalized
medicine? That’s not an idle question as new technologies help
both medical specialties to better understand how molecular processes play
a role in various diseases.
Oncology may prove to be the powerful force that encourages collaboration
and greater clinical integration between radiology and pathology.The catalyst in
the process will be the use of molecular imaging and molecular diagnostics in
tandem to provide personalized medicine services to patients. While scouting
speakers and topics for the upcoming Molecular Summit on Integration of In Vivo
and In Vitro Diagnostics (www.molecular-summit.com), our editor heard this scenario
from experts in molecular imaging and their molecular pathologist colleagues
who were working together, generally in advanced research settings.
Admittedly, there are only a limited number of sites where molecular
imaging and molecular diagnostics are being integrated and used in innovative
ways to improve diagnosis, identify the most promising therapies, and
monitor the patient’s progress.Most of this is high science and definitely several
years from clinical acceptance and daily use.
On the other hand, there is undeniable enthusiasm as the molecular
pathologists and their imaging colleagues describe successes and share their
vision. These physicians express great confidence that their approach to integrating various molecular procedures will provide physicians with powerful
new tools to diagnosis patients and cure their disease.
I call your attention to these points for a simple reason. Across healthcare,
pathologists are not the only physicians immersing themselves in genetic
medicine and molecular technologies. Within their own specialties, radiologists,
cardiologists, and other classes of physicians are doing innovative
research. Add to that mix the health informaticians who are working
earnestly to pour disparate sets of clinical data into sophisticated software
programs, crunch that data in complex ways, then deliver clinically-relevant
information to the attending physician.
Thus, it would be naive to say that lab medicine will hold the lock and key on
molecular information. Across the spectrum of medicine, experts in many different
fields are tinkering with genetic science and molecular technologies. That
makes it likely that pathologists will bemore collaborative in coming years.
2008's Top Ten Lab Stories
Lacked Disruptive Impact
Lab industry enjoys a time of relative quiet
with few management storm clouds on horizon
CEO SUMMARY: For the first time in recent memory, a year
has passed without major tumult or disruptive change in the laboratory
industry. Our list of the Top Ten Most Important Stories of
2008 reflects a rather quiet year when compared to most years of
this decade. However, events continue to unfold in healthcare and
in the laboratory profession which require strategic responses by
most clinical laboratories and pathology groups. Here's a look at
this year’s most interesting developments.
No. 1 Medicare Lab Competitive Bidding
Stopped by Courts and by Congress
No. 2 Consumers Show How Quickly They
Can Move the Lab Testing Needle
No. 3 Consumers Show How Quickly They
Can Move the Lab Testing Needle
No. 4 Prime Time For Rapid Molecular
Tests of Infectious Diseases
No. 5 Digital Pathology Systems: Coming
Soon to a Laboratory Near You!
No. 6 "System of Prevention" Management
Gains Wider Acceptance in Healthcare
No. 7 It’s ISO 15189 for 2008 as U.S. Labs
Can Now Pursue this QMS Accreditation
No. 8 Feds Announce a Date for ICD-10,
Providers Face Up to the Inevitable
No. 9 Cracks in the Lab Service Facade
Reveal Underfunding Consequences
No. 10 2008—Not a Year for Big Lab Deals
As Relative Calm Rules Lab Market
Multi-Modality Diagnosis Heading for Lab Medicine
Systems biology shifts thinking towarrd multi-specialty approach
CEO SUMMARY: At the upcoming Molecular
Summit in Philadelphia on February 10-11,
2009, pathologists, molecular imaging experts,
and informaticians will share the latest developments
on the integration of in vivo (imaging)
and in vitro (pathology) diagnostics. A major
theme will be discussion about multi-modality
diagnostics and how this new discipline—driven
by advances in genetics and personalized
medicine—will reshape laboratory medicine as
it is practiced today.
Marketplace Update: LabCorp Talks to Its Clients
About Service Enhancements
CEO David King invites clients to respond
directly to him with ideas and suggestions
Momentum Continues
for Digital Pathology
FDA clears reading of Aperio's digital
progesterone receptor slides on computer monitor
CEO SUMMARY: Last month, digital imaging in pathology
gained additional momentum with the latest FDA clearance.
Aperio Technologies, Inc., now has FDA clearance to market
its slide scanning system for reading digital progesterone
receptor (PR) slides on a computer monitor. Aperio plans to
file an application next year with the FDA for clearance to use
its digital pathology imaging system for the reading of digital
H&E breast tissue slides on a computer monitor.
INTELLIGENCE: Late & Latent
POCT TROPONIN
STUDY REPORTS GOOD
TAT RESULTSADD TO: POC Testing |